/
Neurology
Migraine
73
Pipeline Programs↗
184
Active Trials↗
78
Companies Involved↗
Migraine is a moderately active landscape with 73 programs across 78 companies. The most active players are AbbVie, Bristol-Myers Squibb, Lundbeck. 15 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical53
Phase 11
Phase 315
Approved
No programs
Analysis
Modality Breakdown
97%
Small molecule
64 of 66 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 66 classified programs, each share of the total. Modality classified for 96% of 73 pipeline programs.
Analysis
Trial Status
746
clinical trials
Completed440 · 59%
Recruiting104 · 14%
Unknown status55 · 7%
Active, not recruiting37 · 5%
Terminated37 · 5%
Not yet recruiting34 · 5%
Other39 · 5%
Clinical Trials
Trial Activity
746 trials
Page 1 of 50
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)